Safety and Efficacy of Fluticasone and Beclomethasone in Moderate to Severe Asthma
暂无分享,去创建一个
[1] D. Chappard,et al. Altered trabecular architecture induced by Corticosteroids: A Bone Histomorphometric Study , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[2] A. Woolcock,et al. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. , 1996, American journal of respiratory and critical care medicine.
[3] G. Bootsma,et al. Fluticasone propionate does not influence bone metabolism in contrast to beclomethasone dipropionate. , 1996, American journal of respiratory and critical care medicine.
[4] R. Eastell,et al. Comparison of rates of bone loss from the spine measured using two manufacturers' densitometers , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[5] M. Johnson,et al. Fluticasone propionate--an update on preclinical and clinical experience. , 1995, Respiratory medicine.
[6] Klaus Engelke,et al. Universal standardization for dual X‐ray absorptiometry: Patient and phantom cross‐calibration results , 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[7] Jacques P. Brown,et al. Effects of long-term use of high-dose inhaled steroids on bone density and calcium metabolism. , 1994, The Journal of allergy and clinical immunology.
[8] M. Nieminen,et al. Bone mineral density in asthmatic women on high-dose inhaled beclomethasone dipropionate. , 1994, Bone.
[9] C. Rosen,et al. Glucocorticoids and osteoporosis. , 1994, Endocrinology and metabolism clinics of North America.
[10] P. Ind,et al. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid , 1994, The Lancet.
[11] M. Ip,et al. Decreased bone mineral density in premenopausal asthma patients receiving long-term inhaled steroids. , 1994, Chest.
[12] P. Leblanc,et al. A comparison of fluticasone propionate 200 μg/day with beclomethasone dipropionate 400 μg/day in adult asthma , 1994, Allergy.
[13] J. Hébert,et al. Evaluation of fluticasone propionate (500 μg day−1) administered either as dry powder via a Diskhaler® inhaler or pressurized inhaler and compared with beclomethasone dipropionate (1000 μg day−1) administered by pressurized inhaler , 1993 .
[14] L. Fabbri,et al. Comparison of fluticasone propionate with beclomethasone dipropionate in moderate to severe asthma treated for one year. International Study Group. , 1993, Thorax.
[15] G. Marone,et al. A comparison of fluticasone propionate, 1 mg daily, with beclomethasone dipropionate, 2 mg daily, in the treatment of severe asthma. International Study Group. , 1993, The European respiratory journal.
[16] J E Cotes,et al. Lung volumes and forced ventilatory flows , 1993, European Respiratory Journal.
[17] P. Autio,et al. Systemic glucocorticoid treatment decreases serum concentrations of carboxyterminal propeptide of type I procollagen and aminoterminal propeptide of type III procollagen , 1992, The British journal of dermatology.
[18] M. Hyland,et al. The Living with Asthma Questionnaire. , 1991, Respiratory medicine.
[19] P. Geusens,et al. Locomotor side-effects of corticosteroids. , 1991, Bailliere's clinical rheumatology.
[20] J. Eisman,et al. Corticosteroid effects on proximal femur bone loss , 1990, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[21] S. Harding. The human pharmacology of fluticasone propionate. , 1990, Respiratory medicine.
[22] A. Adinoff,et al. Steroid-induced fractures and bone loss in patients with asthma. , 1983, The New England journal of medicine.
[23] J. Poloniecki,et al. The Two Period Cross Over Trial , 1982 .
[24] M. Hills,et al. The two-period cross-over clinical trial. , 1979, British journal of clinical pharmacology.